Newsroom

Sorted by: Latest

-

ACCELQ es reconocida como líder y favorita de los clientes en The Forrester Wave™ for Autonomous Testing Platforms

DALLAS--(BUSINESS WIRE)--Forrester a designado a ACCELQ como líder en The Forrester Wave™: Autonomous Testing Platforms, en el cuarto trimestre de 2025. Este reconocimiento marca la tercera edición consecutiva del Wave en la que ACCELQ es distinguida como Líder. Cabe destacar que la evaluación puso un fuerte énfasis en la innovación en inteligencia artificial generativa y en la adopción real por parte de los clientes. ACCELQ obtuvo las puntuaciones más altas tanto en capacidades como en visión...
-

Northern Trust Asset Management Forecasts AI-Driven Strength in Private Markets; United States, Japan and Australia to Lead Equity Returns over Next Decade

CHICAGO & LONDON--(BUSINESS WIRE)--Northern Trust Asset Management published its Capital Market Assumptions (CMA) 2026 Edition, forecasting improving and stable fixed income returns; market-leading U.S., Japanese and Australian equities; resilient real assets; and strong private market prospects fueled by innovation over the next decade. The CMA also identifies three key long-term trends to markets and the global economy — Rising Innovation and Declining Demographics, the Global Shift to Self-R...
-

Altria to Host Webcast of 2025 Fourth-Quarter and Full-Year Results

RICHMOND, Va.--(BUSINESS WIRE)--Altria to Host Webcast of 2025 Fourth-Quarter and Full-Year Results...
-

EndoQuest Receives FDA Approval to Initiate Final Stage of PARADIGM Trial

HOUSTON--(BUSINESS WIRE)--EndoQuest Robotics, Inc., a pioneering leader in endoluminal robotic surgical technology, today announced that the U.S. Food and Drug Administration (FDA) has approved initiation of the next and final stage of its pivotal multicenter trial, the PARADIGM Trial (Prospective Assessment of a Robotic Assisted Device in Gastrointestinal Medicine). The PARADIGM Trial is an Investigational Device Exemption (IDE) study evaluating EndoQuest’s Endoluminal Surgical (ELS) System fo...
-

eSentire Warns Businesses: Hackers are After Your Employees’ Account Credentials, as Account Compromise Threats Surge 389% in 2025

WATERLOO, Ontario--(BUSINESS WIRE)--eSentire's new 2026 CYBERTHREAT LANDSCAPE REPORT found a 389% increase year over year in account compromise identity-based threats in 2025 ....
-

Unum Group Declares Quarterly Dividend of $0.460 Per Share of its Common Stock

CHATTANOOGA, Tenn.--(BUSINESS WIRE)--Effective January 15, 2026, the Unum Group (NYSE: UNM) Board of Directors declared a quarterly dividend of $0.460 per share on its common stock to be paid February 20, 2026, to stockholders of record as of January 30, 2026. About Unum Group Unum Group (NYSE: UNM), a leading international provider of workplace benefits and services, has been helping workers and their families thrive for more than 175 years. Through its Unum and Colonial Life brands, the compa...
-

Sikich and Boston University Questrom School of Business Announce Strategic Collaboration

CHICAGO--(BUSINESS WIRE)--Sikich and Boston University's Questrom Business School will pioneer intelligent delivery in life sciences, insurance and legal sectors....
-

Sand Grove Capital Management LLP UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Sand Grove Capital Management LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries mu...
-

CFP Board Reports Record Growth in CFP® Professionals and Exam Candidates in 2025

WASHINGTON--(BUSINESS WIRE)--CFP Board today reported a milestone year in 2025, with record numbers of new CFP® certificants and exam candidates....
-

Henry Schein Enters Exclusive Distribution Agreement for CytoChip’s CLIA-Waived Hematology Analyzer

IRVINE, Calif.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care...